Gossamer Bio (NASDAQ:GOSS) Given New $20.00 Price Target at HC Wainwright

Gossamer Bio (NASDAQ:GOSSGet Rating) had its price objective reduced by equities research analysts at HC Wainwright from $25.00 to $20.00 in a report released on Tuesday, The Fly reports. HC Wainwright’s price target would suggest a potential upside of 120.26% from the stock’s current price.

GOSS has been the subject of a number of other research reports. Piper Sandler dropped their price target on Gossamer Bio from $26.00 to $15.00 in a research report on Monday. UBS Group initiated coverage on Gossamer Bio in a report on Wednesday, April 6th. They set a “buy” rating and a $19.00 price objective on the stock. Sumitomo Mitsui Financial Group raised Gossamer Bio from a “neutral” rating to an “outperform” rating and set a $24.00 price objective on the stock in a report on Monday, January 10th. Zacks Investment Research raised Gossamer Bio from a “sell” rating to a “hold” rating in a report on Tuesday, March 8th. Finally, Raymond James initiated coverage on Gossamer Bio in a report on Monday, April 18th. They set an “outperform” rating and a $19.00 price objective on the stock. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $20.00.

Shares of GOSS opened at $9.08 on Tuesday. The company has a market cap of $694.41 million, a PE ratio of -2.91 and a beta of 1.03. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 1.47. The stock has a 50-day moving average price of $9.08 and a 200-day moving average price of $10.50. Gossamer Bio has a 12-month low of $6.65 and a 12-month high of $14.30.

Gossamer Bio (NASDAQ:GOSSGet Rating) last issued its quarterly earnings results on Thursday, March 3rd. The company reported ($0.74) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.74). During the same period in the prior year, the company posted ($0.88) EPS. As a group, analysts predict that Gossamer Bio will post -3.09 earnings per share for the current year.

In other news, EVP Caryn Peterson sold 6,279 shares of Gossamer Bio stock in a transaction that occurred on Wednesday, March 16th. The stock was sold at an average price of $8.28, for a total value of $51,990.12. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Waage Christian sold 10,722 shares of Gossamer Bio stock in a transaction that occurred on Wednesday, March 23rd. The stock was sold at an average price of $8.91, for a total value of $95,533.02. The disclosure for this sale can be found here. Insiders sold a total of 41,038 shares of company stock worth $358,542 over the last ninety days. Insiders own 23.30% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP bought a new stake in shares of Gossamer Bio during the third quarter valued at approximately $133,000. Eversept Partners LP bought a new stake in shares of Gossamer Bio during the third quarter valued at approximately $1,884,000. SG Americas Securities LLC bought a new stake in shares of Gossamer Bio during the third quarter valued at approximately $614,000. Trexquant Investment LP bought a new stake in Gossamer Bio in the third quarter worth $237,000. Finally, Metropolitan Life Insurance Co NY boosted its holdings in Gossamer Bio by 84.3% in the third quarter. Metropolitan Life Insurance Co NY now owns 15,971 shares of the company’s stock worth $201,000 after acquiring an additional 7,306 shares in the last quarter. Institutional investors own 71.59% of the company’s stock.

About Gossamer Bio (Get Rating)

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis.

Read More

The Fly logo

Analyst Recommendations for Gossamer Bio (NASDAQ:GOSS)

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.